Showing results (111-120 of 129) with videos related to
Sort By:
Pageof 13
Gut|October 9, 2024
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis BDavid Z Pan, Cameron M Soulette, Abhishek Aggarwal, et al.Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moietyDouglas K Hutchinson, Charles A Flentge, Pamela L Donner, et al.Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 3, 2016
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infectionJia-Horng Kao, Rong-Nan Chien, Ting-Tsung Chang, et al.Hepatology International|April 12, 2018
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b studyLai Wei, Qing Xie, Jin Lin Hou, et al.Journal of Hepatology|April 29, 2023
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis deltaJulius Hollnberger, Yang Liu, Simin Xu, et al.Journal of Gastroenterology and Hepatology|February 5, 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusWan-Long Chuang, Rong-Nan Chien, Cheng-Yuan Peng, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocketKent D Stewart, Jeffrey R Huth, Teresa I Ng, et al.Pageof 13